GnRH stimulates gonadotropin secretion, which desensitizes unless the releasing hormone is secreted or administered in a pulsatile fashion. The mechanism of desensitization is unknown, but as the GnRH receptor is G protein coupled, it might involve G proteincoupled receptor kinases (GRKs). Such kinases phosphorylate the intracellular regions of seven-transmembrane receptors, permitting ␤-arrestin to bind, which prevents the receptor from activating G proteins. Here, we tested the effect of GRKs and ␤-arrestins on GnRHinduced inositol trisphosphate (IP 3 ) production in COS cells transfected with the GnRH receptor complementary DNA. GRK2, -3, and -6 overexpression inhibited IP 3 production by 50 -75% during the 30 sec of GnRH treatment. Coexpression of GRK2 and ␤-arrestin-2 suppressed GnRH-induced IP 3 production more than that of either alone. Immunocytochemical staining of rat anterior pituitary revealed that all cells expressed GRK2, -3, and -6; all cells also expressed the ␤-arrestins. Western blots on cytosolic extracts of rat pituitaries revealed the presence of GRK2/3 and ␤-arrestin-1 and -2. The expression of GRKs and ␤-arrestins by gonadotropes and their inhibition of GnRH-stimulated IP 3 production in COS-1 cells expressing the GnRH receptor suggest a potential regulatory role for the GRK/␤ arrestin paradigm in GnRH receptor signaling. (Endocrinology 139: [1781][1782][1783][1784][1785][1786][1787][1788] 1998) 
D ESENSITIZATION of LH secretion is a prominent fea-
ture of GnRH action. It occurs whenever GnRH is administered or secreted in a continuous mode (1, 2) , but it can be avoided by GnRH administration in a pulsatile fashion that mimics its in vivo pattern of secretion (1) . The mechanisms of desensitization are unknown, but studies of it have been enhanced by the molecular cloning, nucleotide sequencing, and heterologous expression of the GnRH receptor (3, 4) . Desensitization may involve one or both of the protein families, the regulators of G protein signaling (RGSs) or G protein-coupled receptor kinases (GRKs) , that are thought to be involved in desensitizing the G protein-coupled receptor family, of which the GnRH receptor is a member. Recently discovered RGSs (5-7) bind the G ␣-subunit, thereby limiting its activation of the second messenger pathway (8) . We have shown that RGS3 inhibits GnRH-stimulated inositol trisphosphate (IP 3 ) production in cotransfected COS-1 cells and is present in gonadotropes, suggesting a potential regulatory role for this particular RGS in GnRH-induced desensitization (9) .
A second, more extensively studied mechanism of G protein-coupled receptor desensitization involves the GRK/␤ arrestin families of proteins (10) . This mechanism, which has been most intensively studied for the ␤ 2 -adrenergic receptor, involves agonist-specific induced phosphorylation of intracellular regions of the receptor that permits ␤-arrestins to bind, preventing G protein association with the receptor (11) . In a previous study (12) , we reported the presence in ␣T3-1 gonadotropes of GRK2, -3, and -6 and hypothesized that the GRK/␤ arrestin paradigm might apply to the GnRH receptor.
Insofar as we are aware, the GRK/␤ arrestin mechanism of signal modulation has not been tested for its applicability to the GnRH receptor and its associated second messenger generation. Therefore, we have determined the effects of selected GRKs and ␤-arrestin-1 and -2 on GnRH-stimulated IP 3 production in a heterologous cell system.
Materials and Methods

Cell cultures and transfections
COS-1 cells derived from monkey kidney were obtained from the American Type Culture Collection (Rockville, MD) and cultured at 37 C in DMEM supplemented with 1000 IU/ml penicillin, 100 g/ml streptomycin, and 10% FBS in a humidified chamber containing an atmosphere of 8% CO 2 as described previously (13) . The COS-1 cells were subcultured twice weekly at a ratio of 1:8 -1:12 for 6 -12 months; then they were replaced with a new aliquot of cells that were thawed and expanded from frozen stocks stored in liquid nitrogen.
In preparation for transfections of COS-1 cells (13), we collected the cells in the afternoon from subconfluent cultures (Ͻ15 ϫ 10 6 cells/T-175 flasks) using a trysin-EDTA solution (Sigma Chemical Co., St. Louis, MO) and seeded them (3 ϫ 10 6 cells in 10 ml DMEM/10% FBS) into 60-mm Falcon petri dishes. The cells were incubated overnight before being transfected the next morning. One hundred microliters of Lipofectamine (Life Technologies, Gaithersburg, MD) in 700 l OptiMEM I (Life Technologies) were mixed with 800 l OptiMEM containing the vector with its complementary DNA (cDNA) insert to be transfected. After 15-to 30-min incubation, the Lipofectamine-DNA complexes and 6.4 ml OptiMEM were placed on the cells, which were then put in the incubator for 5-8 h before 8 ml DMEM/20% FBS was added. The cells were incubated for 20 -24 h, after which the medium was aspirated and replaced with 12 ml DMEM/10% FBS. Seventy-two hours after the initiation of transfection, cells were harvested for preparation of membrane fractions for use in receptor radioassays or were treated with d-Ala 6 -desGly 10 -GnRH-ethylamide (GnRH-A) in preparation for measurements of IP 3 .
cDNAs for transfections
The construction of the cDNA representing the rat GnRH receptor used for transfections of COS-1 cells has been described and validated in detail previously (13) . The cDNA bears the nucleotide sequence encoding the HA-1 epitope tag at its 5Ј-end and was fused using recombinant DNA methodology to the wild-type GnRH receptor cDNA from which the untranslated 5Ј-and 3Ј-sequences had been removed by PCR. It was subcloned into the eukaryotic expression vector pcDNA 3 (Invitrogen, Carlsbad, CA). After transfection and expression in COS-1 cells, this N-terminal epitope-tagged GnRH receptor shows a [
125 I]-GnRH-A binding affinity identical with that of the wild-type receptor and mediates a robust GnRH stimulation of IP 3 production in COS-1 cells (13) .
The cDNAs representing bovine GRK2 (in expression vector pBC ␤ARK-1) (14), bovine GRK3 (in expression vector pBC ␤ARK-2) (14), and human GRK6 (in expression vector pBCGRK6) (15) were provided by Dr. Jeffrey L. Benovic. cDNAs representing the ␤-arrestins (in the expression vectors pCMV5-rat ␤-arrestin-1 and pCMV5-rat ␤-arrestin-2) (16) were provided by Dr. Robert J. Lefkowitz.
RRA for GnRH
GnRH-A was iodinated with Na 125 I using chloramine-T as described by Clayton et al. (17) , and purified using carboxymethyl-cellulose and ammonium acetate. Specific radioactivities estimated as described by Wiener and Reith (18) were about 700 Ci/g. COS-1 cell membranes (35- 3 were separated by centrifugation at 12,000 -15,000 ϫ g for 5 min. The precipitate was dissolved in 50 l 0.15 n NaOH and placed in a vial for liquid scintillation spectroscopy.
In preparation for GnRH-A treatment of the transfected COS-1 cells, we removed and discarded the incubation medium, replaced it with 3 ml 0.1% BSA-DMEM, and preincubated the cells for 1 h. Then, the preincubation medium was replaced with 1 ml DMEM containing 10 Ϫ7 m GnRH-A; treatments lasted 0, 10, 20, or 30 sec. IP 3 was extracted from COS-1 cells by replacing the treatment medium with 1 ml cold 16.6% trichloroacetic acid. The cells were then scraped from the bottoms of the dishes, transferred to microfuge tubes, vortexed, incubated on ice for 15 min, and centrifuged for 1 min at 14,000 ϫ g, and the supernatant was removed and allowed to stand at room temperature for 15 min. The samples were then extracted four times with 2 vol diethyl ether, and the samples were heated at 65 C for 15 min to evaporate the ether. The samples were then stored at 4 C until use in the IP 3 RRA.
Antibodies
Antibodies to GRK2, -3, and -6 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and used for immunocytochemistry on rat anterior pituitary cells. They were prepared in rabbits against synthetic peptides corresponding to the carboxyl-termini of human GRK2, -3, and -6 (amino acids 675-689, 675-688, and 525-544, respectively). The antibodies were affinity purified using their respective synthetic peptides attached to a solid phase. Antibodies against each GRK react with their cognate GRKs of mouse, rat, human, and bovine origin, but there is no cross-reactivity among the different GRKs.
Antiserum to rat GRK3 was provided by Dr. Robert J. Lefkowitz; it was used for Western blot analysis of rat anterior pituitary cells. The antiserum was produced in rabbits to the carboxyl-terminal 222 amino acids of rat GRK3 (amino acids 467-688) fused to GST (rabbit 7428) (20) . This antiserum binds both GRK3 and -2, as there is 76% homology between the amino acid sequences of the C-termini of these two proteins (20) ; indeed, it detects GRK2 much more strongly than GRK3 (20) .
Antiserum to rat ␤-arrestin-2 was also provided by Dr. Robert J. Lefkowitz; it was used for both immunocytochemistry and Western blots. The antiserum was prepared in rabbits against a glutathione-Stransferase fusion protein containing the carboxyl-terminal 78 amino acids (amino acids 333-410) of rat ␤-arrestin-2 (rabbit 7435-3) (16). The antiserum contains antibodies reacting both with ␤-arrestin-2 and ␤-arrestin-1 due to the 55% amino acid homology between the two proteins (16).
Immunocytochemistry and immunoblotting
Rat anterior pituitary glands were dispersed using trypsin into single cell suspensions for immunocytochemistry as previously described (21) . After attachment to glass microscope slides using poly-l-lysine, the cells were fixed with freshly prepared 3.5% paraformaldehyde for 8 min and permeabilized with 0.1% Nonidet P-40 for 15 min. Staining was performed with the Vectastain ABC rabbit kit (Vector Laboratories, Burlingame, CA) using the instructions supplied by the manufacturer. Antibodies against GRK2, -3, and -6 were used at a concentration of 1 g/ml, whereas antiserum against ␤-arrestin-2 was used at a dilution of 1:5000; all were incubated with the cells overnight at room temperature. The diaminobenzidine substrate was incubated with the cells until the appropriate level of color had developed (usually about 1 min).
Immunoblots for GRKs and ␤-arrestins were performed on rat anterior pituitary cytosol preparations. Pituitary glands from female rats were homogenized in a Dounce homogenizer (Kontes Co., Vineland, NJ) in 10 mm Tris-HCl (pH 7.4). The homogenate was centrifuged at 40,000 ϫ g for 10 min; the supernate was removed and mixed with sample buffer in preparation for protein separation in SDS-PAGE. The sample was reduced by heating at 95 C for 5 min in 10% ␤-mercaptoethanol and then electrophoresed on an 8% gel. Separated proteins were electroblotted onto nylon membranes (0.1-m pore size; Immobilon-P SQ , PVDF Transfer Membrane, Millipore Corp., Bedford, MA). The membranes were then blocked in a solution of 5% nonfat dry milk in 0.05 m PBS containing 0.02% Tween-20 for 1 h. The primary antisera diluted in blocking solution (GRK3 at 1:1000 and ␤-arrestin-2 at 1:200) were incubated with the strips for 1 h at room temperature. After washing the membrane three times for 10 min each time, we incubated it for 1 h at room temperature with alkaline phosphatase-conjugated goat antirabbit antiserum (Sigma) diluted 1:1000 in blocking solution. Finally, the strip was developed for 5 min in CDP-STAR Chemiluminescence Reagent (New England Nuclear Life Science Products, Boston, MA). Immunoreactive proteins were detected using the Eagle Eye II Still Videosystem together with its accompanying Eagle Sight Image Capture and Analysis Software (Stratagene, La Jolla, CA).
Data analysis
The results are presented as the mean Ϯ sem of at least three independent experiments. The statistical tests were either one-or two-way ANOVA as indicated in the figure legends. Statistical analysis was performed using SigmaStat Statistical Software for Windows (Jandel Scientific, San Rafael, CA).
Results
Inhibitory effects of GRKs on GnRH-induced IP 3 production
We have shown previously that COS-1 cells transfected with and expressing the epitope-tagged rat GnRH receptor show a brief rise (30 -60 sec) in IP 3 production when treated with GnRH (13) . In the present studies we cotransfected COS-1 cells with 0.83 g GRK2, -3, or -6 cDNA together with 0.83 g of the GnRH receptor cDNA to determine whether GnRH-stimulated IP 3 production was inhibited by the GRKs. As illustrated in Fig. 1 , in four experiments we observed 25-50% inhibitions of GnRH-stimulated IP 3 production during the 30 sec of hormone treatment. Although GRK3 expression showed the greatest apparent inhibition, it was not significantly different from that in the GRK2 and -6 groups (P Ͼ 0.05). However, inhibition in all three GRK groups was significantly less than that in the control group (P Ͻ 0.05). Calculated as the area under the curve, inhibition by GRK3 was 56%, that by GRK2 was 23%, and that by GRK6 was 15%. The inhibition by GRKs of GnRH-stimulated IP 3 production was not due to suppression of GnRH receptor expression, as membrane binding of [ 125 I]GnRH-A did not differ statistically among the groups: control, 353 Ϯ 47 (mean Ϯ sem) dpm/g membrane protein; GRK2, 403 Ϯ 47; GRK3, 363 Ϯ 59; and GRK6, 348 Ϯ 43.
In the preceding experiments, we transfected COS-1 cells with a relatively small amount of cDNA (0.83 g) representing the GRKs. To determine whether larger amounts of cDNA would induce greater decreases in GnRH-stimulated IP 3 increases, we transfected COS-1 cells with 1.7 or 6.7 g GRK2 or -3. IP 3 concentrations were measured at a single time point (20 sec) after the initiation of GnRH-A treatment. As expected, greater inhibitions were observed (Fig. 2) . For GRK2, in which 37% inhibition was observed at 20 sec when 0.83 g cDNA was transfected (Fig. 1) , 54% and 67% inhibitions were observed when 1.7 or 6.7 g cDNA, respectively, were transfected (Fig. 2) . For GRK3, in which a 45% inhibition was observed 20 sec after GnRH-A treatment began when 0.83 g cDNA was transfected (Fig. 1) , 44% and 65% inhibitions (Fig. 2) were observed when 1.7 or 6.7 g cDNA, respectively, were transfected. Parenthetically, although GRK treatment significantly suppressed GnRH-Astimulated IP 3 production in all four groups (Fig. 2) 
In conclusion, these results demonstrate that overexpression of GRK2 and -3 causes robust inhibition of GnRH-A-stimulated second messenger responses in COS-1 cells. FIG. 1. GRK2, -3 , and -6 inhibit GnRH-stimulated cellular IP 3 production. COS-1 cells were cotransfected with cDNAs representing the GnRH receptor (0.8 g) and GRK2, -3, or -6 (0.8 g). Seventy-two hours after the initiation of transfection, the cells were treated with 10 Ϫ7 M GnRH-A for 0, 10, 20, or 30 sec. Intracellular IP 3 levels were measured by RRA. Data from four independent experiments are presented as the mean Ϯ SEM and were analyzed by two-way ANOVA using Dunnett's method (all pairwise multiple comparison procedure) to detect significant differences (P Ͻ 0.05). As the asterisks indicate, values in the GRK2, -3, and -6 treatment groups were significantly lower than those in the control group, but were not significantly different from each other.
FIG. 2.
Increased levels of GRK2 and -3 expression increase their inhibitory effects on GnRH-stimulated cellular IP 3 production. COS-1 cells were cotransfected with GnRH receptor cDNA (0.8 g) and GRK2 cDNA (1.7 or 6.7 g) or GRK3 cDNA (1.7 or 6.7 g) and treated 72 h later with 10 Ϫ7 M GnRH-A for 20 sec before collection of cells for IP 3 measurements. The IP 3 concentrations presented are the net differences between the zero time point (no GnRH-A treatment) and the 20 sec point (10 Ϫ7 M GnRH-A). The data were analyzed using one-way ANOVA, and significant differences (P Ͻ 0.05) were identified by Dunnett's method. *, Significant difference from the appropriate control group; **, 6.7 g GRK3 cDNA were more inhibitory than 1.7 g GRK3 cDNA.
Inhibitory effect of ␤-arrestin-2 on GnRH-induced IP 3 production
The classical paradigm for GRK inhibiting second messenger responses to ligands that interact with G proteincoupled receptors is GRK phosphorylating intracellular regions of the receptors, permitting ␤-arrestin binding to the receptor, which prevents it from activating G proteins (11) . To determine whether ␤-arrestins are active in the GnRH receptor signaling system, we cotransfected ␤-arrestin-1 or -2 cDNAs together with GRK2 or -3 cDNAs and GnRH receptor cDNA; the COS-1 cells were then treated with GnRH-A for IP 3 measurements at a single time point (20 sec). Four experiments were performed. In three, 0.8 g GnRH receptor cDNA and 0.8 g GRK cDNA were used for transfection, whereas in one experiment, 1.7 g of the two kinds of cDNAs were used for transfection. In all four experiments, the cells were transfected with 6.7 g ␤-arrestin cDNAs. Where appropriate, 0.8 g pcDNA 3 vector or 6.7 g pCMV5 vector were used to equalize the total amount of cDNAs transfected.
The results are shown in Fig. 3 . As expected from the results depicted in Figs. 1 and 2, GRK2 and GRK3 transfections alone inhibited GnRH-stimulated IP 3 production significantly (P Ͻ 0.05 vs. the control group). The inhibition for both GRKs was 37%, which compares favorably with the 37% and 45% inhibitions observed 20 sec after the initiation of GnRH-A treatment with GRK2 and GRK3, respectively (Fig.  1) , where 0.8 g GRK cDNAs was also transfected. Transfections of the ␤-arrestins alone did not result in significant inhibitions of hormone-stimulated intracellular IP 3 levels (Fig. 3) . Cotransfections of the GRKs together with the ␤-arrestins resulted in statistically significant inhibition relative to the control value (P Ͻ 0.05) and to that with ␤-arrestins alone (P Ͻ 0.05), but not when compared with that produced by GRKs alone (P Ͼ 0.05). However, the GRK2 and ␤-arrestin-2 group approached statistically significant inhibition relative to that with GRK2 alone (P ϭ 0.06; Fig. 3). [
125 I]GnRH binding did not differ significantly among the nine groups (P Ͼ 0.05, by one-way ANOVA): control, 137 Ϯ 19 (mean Ϯ sem) dpm/g membrane protein; GRK2, 147 Ϯ 25; GRK3, 157 Ϯ 28; ␤-arrestin-1, 167 Ϯ 20; ␤-arrestin-2, 128 Ϯ 37; GRK2 plus ␤-arrestin-1, 176 Ϯ 21; GRK2 plus ␤-arrestin-2, 136 Ϯ 33; GRK3 plus ␤-arrestin-1, 155 Ϯ 21; and GRK3 plus ␤-arrestin-2, 121 Ϯ 28.
The inhibition of IP 3 production by GRK2 and ␤-arrestin-2 (Fig. 3) , which approached but did not reach statistical significance (P ϭ 0.06), prompted us to examine their effects in greater detail. Instead of measuring IP 3 levels once (20 sec) after treatment with GnRH-A (Fig. 3) , we increased the number of measurements to three at 10, 20, and 30 sec (Fig. 4) . GRK2 cDNA (0.8 g) and ␤-arrestin-2 cDNA (6.7 g) alone significantly inhibited (P Ͻ 0.05) IP 3 production relative to the control (Fig. 4) ; however, the two treatment groups were not significantly different (P Ͼ 0.05) from each other. The combined expression of GRK2 and ␤-arrestin-2 inhibited IP 3 production (P Ͻ 0.05) more than either alone (Fig. 4) . Expressed as the area under the curve, ␤-arrestin-2 inhibited IP 3 production by 20%, GRK2 inhibited by 31%, and GRK2 plus ␤-arrestin-2 inhibited by 49%. As in earlier experiments, FIG. 3 . Effect of expression of GRK2 or -3, ␤-arrestin-1 or -2, or GRK plus ␤-arrestin on GnRH-stimulated cellular IP 3 production. COS-1 cells were cotransfected with GnRH receptor cDNA (0.8 g) and GRK2 or -3 cDNAs (0.8 g) alone or in combination with ␤-arrestin-1 or -2 cDNAs (6.7 g each). Seventy-two hours later, the cells were treated with 10 Ϫ7 M GnRH-A for 20 sec before measurements of IP 3 production. The IP 3 concentrations presented are the net differences between the zero time point (no GnRH-A treatment) and the 20 sec point (10 Ϫ7 M GnRH-A treatment). The data were analyzed using one-way ANOVA, with significant differences (P Ͻ 0.05) identified by Bonferroni's method. *, Significant difference from the control group; **, significant differences from the ␤-arrestin-1 or -2 groups; †, P ϭ 0.06 for the comparison of GRK2 plus ␤-arrestin-2 vs. GRK2. 3 production by combined expression of GRK2 and ␤-arrestin-2. COS-1 cells were cotransfected with GnRH receptor cDNA (0.8 g) and GRK2 cDNA (0.8 g), ␤-arrestin-2 cDNA (6.7 g), or GRK2 and ␤-arrestin-2 cDNAs. Seventy-two hours later, the cells were treated with 10 Ϫ7 M GnRH-A for 0, 10, 20, or 30 sec before being collected for IP 3 measurements. Data from three independent experiments are presented as the mean Ϯ SEM and were analyzed by two-way ANOVA using the Student-Newman-Keuls method (an all pairwise multiple comparison procedure) to detect significant differences (P Ͻ 0.05). Values in all three treatment groups were significantly lower than those in the control group; moreover, values in the combined GRK2 and ␤-arrestin-2 group were lower than those in the GRK2 alone and the ␤-arrestin-2 alone groups.
FIG. 4. Enhanced inhibition of GnRH-induced cellular IP
binding of [
125 I]GnRH-A did not differ significantly (P Ͼ 0.05) among the groups: control, 115 Ϯ 21 dpm/g membrane protein (mean Ϯ sem); GRK2, 129 Ϯ 25; ␤-arrestin-2, 101 Ϯ 12; and GRK2 plus ␤-arrestin-2, 95 Ϯ 15.
Presence of GRKs and ␤-arrestins in the anterior pituitary gland
Immunocytochemistry on enzymatically dispersed rat pituitary cells was performed using antibodies directed toward GRK2, -3, and -6 and toward the ␤-arrestins (Fig. 5) . Compared with the normal rabbit Ig control, GRK2 antibodies stained all of the cells darkly (Fig. 5A) . GRK3 antibodies also stained all of the cells, but the staining was less intense than with GRK2 (Fig. 5 ). GRK6 presented a peculiar pattern of staining; the cytoplasm was stained lightly, but still more intensely than in the control group, whereas the nucleoli were intensely stained (Fig. 5A) . ␤-Arrestins also are expressed in all rat pituitary cells, as shown by greater staining with ␤-arrestin antiserum than with the normal rabbit serum control (Fig. 5B) .
Immunoblotting of rat anterior pituitary cytosol preparations using a GRK3 antiserum that reacts both with GRK3 and GRK2 (20) revealed a diffuse immunoreactive band at approximately 70 kDa. This band is assumed to represent primarily GRK2, but also some GRK3, because 1) the antiserum is established to detect GRK2 better than GRK3; 2) both GRK2 and GRK3 were detected in pituitary cells by immunocytochemistry using different GRK2 and -3 antibodies that are specific for the two proteins; and 3) GRK2 and -3 are reported to have similar relative molecular masses (20) and to electrophorese as approximately 70-kDa proteins in human kidney and hamster fibroblast cell lines (22) and in rat nasal neuroepithelium (23) . The identities of the two additional immunoreactive bands (Fig. 6 ) at about 110 and 55 kDa are unknown, but have been detected previously with this antiserum (22) .
Two major bands were detected in immunoblots of rat pituitary extracts (Fig. 6 ) using the antiserum prepared against rat ␤-arrestin-2 (16). This antiserum cross-reacts with both ␤-arrestin-1 and -2; thus, we assume that the approximately 45-kDa band (Fig. 6) is ␤-arrestin-2, and the approximately 50-kDa band (Fig. 6) is ␤-arrestin-1, as these are their reported relative molecular masses in the rat (16) . The identity of the minor immunoreactive band at about 40 kDa (Fig.  6 ) is unknown.
Discussion
Desensitization is defined classically as the waning of a stimulated response in the face of continuous agonist exposure (10). The best-defined mechanism of desensitization among G protein-coupled, seven-transmembrane receptors involves the GRK/␤-arrestin paradigm; the GRKs phosphorylate intracellular loops of receptors permitting ␤-arrestins to bind, thereby preventing receptors from activating G proteins (11, 24, 25) . The GRK/␤-arrestin paradigm has been most intensively studied for the ␤ 2 -adrenergic receptor that activates adenylyl cyclase (11, 24, 25) . However, it also has been described as applying to G protein-coupled receptors FIG. 5. All pituitary cells express endogenous GRK2, -3, and -6 and the ␤-arrestins, as measured by immunocytochemistry. Rat anterior pituitary cells were dispersed with trypsin, fixed with paraformaldehyde, permeabilized with Nonidet P-40, and then stained using the Vectastain ABC kit for rabbit antibodies. A, Antibodies were prepared against carboxyl-terminal peptides from GRK2, -3, and -6 (Santa Cruz Biotechnology). B, Antiserum to rat ␤-arrestin-2 was provided by Dr. Robert J. Lefkowitz; it detects both ␤-arrestin-1 and -2 (16) .
that couple to the G q ␣ protein and hence activate phospholipase C␤1, including the muscarinic m1, m3, and m5 receptors (24); the substance P (NK1) receptor (26) ; endothelin A and B receptors (27) ; and the thrombin receptor (28), among others.
The GnRH receptor has been described as activating the G q ␣ protein (29) and subsequently phospholipase C␤1 (4) to generate the second messengers IP 3 and Ca ϩ2 (4) . According to the results of the present study, the GRK/␤-arrestin paradigm may include the GnRH receptor, as GRK2 and -3 and ␤-arrestin-2 suppress GnRH-stimulated IP 3 production in a transfected heterologous cell system. This inhibition was robust, approaching 70% when relatively high amounts of GRK2 or -3 cDNAs were transfected; moreover, as expected from previous studies (11), coexpression of GRK2 and ␤-arrestin-2 produced a greater inhibition than either alone. These results coupled with our finding of endogenous expression of GRKs and ␤-arrestins in rat anterior pituitary gland strongly suggest an involvement of the GRK/␤-arrestin paradigm in setting the GnRH responsiveness of cells expressing the GnRH receptor.
The substrate specificity of GRKs for various receptors except GRK1 remains problematical (11) . GRK1 (rhodopsin kinase) is expressed primarily in the retina, so its actions seem to be restricted to rhodopsin (30) . GRK2 and -3 are widely distributed and are active at phosphorylating numerous different seven-transmembrane receptors (11, 24, 25) , so it is difficult to identify specific GRK/receptor pairs that interact in vivo. One instance where GRK3 vs. GRK2 specificity is apparent is odorant-induced second messenger production in rat nasal cilia; GRK3 antibodies, but not GRK2 antibodies, block second messenger production (31) . Monoclonal antibodies directed at GRK2/3 and GRK4 -6 were used to show that GRK2/3, but not GRK4 -6, was involved in angiotensin AT 1 receptor phosphorylation (32) . This ablation approach using antibodies to the GRKs is powerful, and it or antisense cDNA ablation approaches (33) are needed to sort out the specific GRKs involved in altering GnRH responsiveness in pituitary gonadotropes.
The arrestin family is comprised of four cytoplasmic proteins, two of which are restricted to the retina (25) , and two of which show a wide distribution in mammalian tissues (11, 24) . The latter two are ␤-arrestin-1 and -2 (␤-arrestin-2 also is known as arrestin-3); they bind to intracellular loops of G protein-coupled receptors that have been phosphorylated by the GRKs (11, 24, 25) . There is very little discrimination among seven-transmembrane receptors by the two types of arrestins (34) . One reported instance of ␤-arrestin specificity is the unique presence of ␤-arrestin-2 in olfactory receptor neurons; antibodies to ␤-arrestin-2 were shown to abolish odorant-induced desensitization (23) . The results of our studies showing that ␤-arrestin-2, but not ␤-arrestin-1, overexpression in the presence of GRK2 overexpression inhibited GnRH-stimulated IP responses in COS-1 cells need to be repeated under more stringent conditions. Even if repeatable, much more rigorous approaches than that used here will be necessary to show specificity for ␤-arrestin-2.
Because our results suggest that the GRK/␤ arrestin paradigm (11) applies to GnRH receptor desensitization, we should be able to observe phosphorylation of the GnRH receptor. However, we have been unable to demonstrate its phosphorylation in a circumstance where pretreatment with FIG. 6. GRK2/3 and ␤-arrestin-1 and -2 are expressed in the pituitary gland, as indicated by immunoblots. Rat anterior pituitary glands were homogenized, and the soluble proteins were separated by SDS-PAGE on 8% gels under reducing conditions. The separated proteins were electroblotted onto nylon membranes, which were then incubated with a GRK3 antiserum (left panel) or a ␤-arrestin-2 antiserum (right panel), followed by incubation with alkaline phosphatase-conjugated goat antirabbit antiserum. Detection of immunoreactive bands was performed using a chemiluminescent substrate. Left panel, The GRK3 antiserum cross-reacts with GRK2, and GRK2 and -3 do not separate in 8% minigels, resulting in a single diffuse immunoreactive band at about 70 kDa labeled GRK 2/3 in the figure. The identities of the bands at approximately 110 and 55 kDa are unknown, but have been detected previously with this antiserum (see text). Right panel, The ␤-arrestin-2 antiserum cross-reacts with ␤-arrestin-1, but the two arrestins can be identified due to their differential mobilities in SDS-PAGE: rat ␤-arrestin-1 is a 50-kDa protein, and rat ␤-arrestin-2 is a 45-kDa protein (see text). The identity of the minor immunoreactive band at approximately 40 kDa is unknown.
GnRH had desensitized GnRH-stimulated IP 3 production in COS-1 cells (13) . Similarly, we have been unable to demonstrate phosphorylation of the GnRH receptor after suppression of GnRH-stimulated IP 3 production by GRK2 and ␤-arrestin-2 (unpublished data). In both instances, we expressed an HA1 epitope-tagged GnRH receptor for immunoprecipitation studies after labeling the cells with 32 P i . Further studies are needed to resolve this discrepancy with the GRK/␤-arrestin paradigm. Parenthetically, the argument (35) that the GnRH receptor is not phosphorylatable because it lacks a C-terminal, cytoplasmic tail (3) is countermanded by the observations that the ␣ 2A -adrenergic (36) and the m2 muscarinic (37) receptors are phosphorylated on sites in their third intracellular loops during desensitization, and that the angiotensin AT 1A (38) and TSH (39) receptors, also desensitized by GRK phosphorylation, are still desensitized after removal of their cytoplasmic tails.
Finally, the possibility should be considered that the GRK/ ␤-arrestin paradigm, rather than being related to desensitization, instead mediates the LH secretory responsiveness levels of gonadotropes induced by gonadal steroids and manifested at different stages of the estrous cycle (40) . A similar idea was earlier considered for thrombin action (28) ; namely, that the rate of thrombin receptor desensitization may set the gain in thrombin receptor signaling and, hence, define a cell's initial sensitivity to thrombin.
In summary, we have provided preliminary evidence in our studies that the GRK/␤-arrestin paradigm of desensitization of G protein-coupled, seven-transmembrane receptors can modulate GnRH receptor signaling. However, more evidence is needed to unequivocally establish such a role. First, we need to provide evidence that the many other characteristics of this paradigm, such as phosphorylation of the receptor and translocation of the GRKs from cytoplasm to membrane (11, 24, 25) to name just two, also apply to the GnRH receptor. Second, we need to ablate the GRKs and ␤-arrestins using antibodies (32) or antisense DNA approaches (33) on pituitary gonadotropes to demonstrate that receptor signaling is altered. These studies are underway.
